ロード中...
17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia and the anti-CD20 monoclonal antibody, rituximab, represents the therapeutic gold standard for more than 2 decades in this pathology, when used in combination with chemotherapy. However, some patients experience treatment resista...
保存先:
| 出版年: | J Immunother Cancer |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6352369/ https://ncbi.nlm.nih.gov/pubmed/30696487 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0509-0 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|